Characterization of zebrafish coagulation cofactors Fviii and Fv mutants and modeling hemophilia A and factor V deficiency
- PMID: 38874909
- PMCID: PMC11230853
- DOI: 10.1097/MBC.0000000000001308
Characterization of zebrafish coagulation cofactors Fviii and Fv mutants and modeling hemophilia A and factor V deficiency
Abstract
The aim of this study is to characterize zebrafish coagulation cofactors fviii and fv mutant fish and assess if they phenocopy classical hemophilia A and factor V deficiency in humans. The embryos from fviii and fv zebrafish heterozygote mutants generated by ENU mutagenesis were purchased from the ZIRC repository. They were reared to adulthood and genotyped. The heterozygote male and female were crossed to get homozygote, heterozygote, and wild-type fish. Functional kinetic coagulation assays and bleeding assays were performed on normal and mutant adult fish, and venous laser injury assays were performed on the larvae. The DNA from fviii and fv mutants were sequenced to confirm if they have a premature stop codon in exon 19, and in exon 2, respectively, and in both mutants, the amino acid glutamine is replaced with a stop codon. Homozygous and heterozygous 5 days post fertilization (dpf) larvae for fviii and fv deficient mutants exhibited prolonged time to occlusion after venous laser injury compared to wild-type controls. The homozygous and heterozygous fviii adult mutants showed modest bleeding and delayed fibrin formation in the kinetic partial thromboplastin time (kPTT) assay with their plasma. fv homozygous larvae had poor survival beyond 12 dpf. However, heterozygous fv mutants exhibited heavy bleeding and prolonged fibrin formation in the kPTT and kPT assay compared with wild-type siblings. Our characterization showed fviii and fv mutants from ZIRC phenocopied to a considerable extent classical hemophilia A and factor V deficiency in humans, respectively. These models should be useful in studying and developing novel drugs that reverse the phenotype and in generating suppressor mutations to identify novel factors that compensate for these deficiencies.
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Conflict of interest statement
Declaration of interest
The authors report no conflict of interest.
Figures








Similar articles
-
Loss of factor VIII in zebrafish rebalances antithrombin deficiency but has a limited bleeding diathesis.Blood Adv. 2025 Jul 8;9(13):3136-3148. doi: 10.1182/bloodadvances.2024013143. Blood Adv. 2025. PMID: 40085950 Free PMC article.
-
The factor (F)VIII K1693N mutation (FVIII-Nara) in a patient with moderate hemophilia A confers resistance to thrombin-catalyzed cleavage at Arg1689 involving P4' position.J Thromb Haemost. 2025 Aug;23(8):2461-2472. doi: 10.1016/j.jtha.2025.05.002. Epub 2025 May 13. J Thromb Haemost. 2025. PMID: 40374115
-
Comparing one stage, chromogenic assay results and discrepancies with bleeding phenotype and genetic variants in females with hemophilia A.J Thromb Haemost. 2025 Feb;23(2):504-512. doi: 10.1016/j.jtha.2024.10.030. Epub 2024 Nov 12. J Thromb Haemost. 2025. PMID: 39536816
-
Clotting factor concentrates for preventing bleeding and bleeding-related complications in previously treated individuals with haemophilia A or B.Cochrane Database Syst Rev. 2021 Aug 18;8(8):CD014201. doi: 10.1002/14651858.CD014201. Cochrane Database Syst Rev. 2021. PMID: 34407214 Free PMC article.
-
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3. Cochrane Database Syst Rev. 2022. PMID: 35593186 Free PMC article.
Cited by
-
CRISPR/Cas9 mediated generation of zebrafish f9a mutant as a model for hemophilia B.Blood Coagul Fibrinolysis. 2025 Apr 1;36(3):90-98. doi: 10.1097/MBC.0000000000001355. Epub 2025 Mar 19. Blood Coagul Fibrinolysis. 2025. PMID: 40127118
-
Generation and characterization of zebrafish f9l mutant confirmed that f9l is f10 like gene.Blood Coagul Fibrinolysis. 2025 Jan 1;36(1):26-33. doi: 10.1097/MBC.0000000000001337. Epub 2024 Nov 29. Blood Coagul Fibrinolysis. 2025. PMID: 39661534
References
-
- Bernal S, Pelaez I, Alias L, Baena M, De Pablo-Moreno JA, Serrano LJ, Camero MD, Tizzano EF, Berrueco R, & Liras A (2021). High Mutational Heterogeneity, and New Mutations in the Human Coagulation Factor V Gene. Future Perspectives for Factor V Deficiency Using Recombinant and Advanced Therapies. Int J Mol Sci, 22(18). 10.3390/ijms22189705 - DOI - PMC - PubMed
-
- Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A, Subcommittee on Factor Viii, F. I. X., Rare Coagulation Disorders of the, S., Standardization Committee of the International Society on, T., & Hemostasis. (2014). Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost, 12(11), 1935–1939. 10.1111/jth.12672 - DOI - PubMed
-
- Dahlback B, & Tran S (2022). A hydrophobic patch (PLVIVG; 1481–1486) in the B-domain of factor V-short is crucial for its synergistic TFPIalpha-cofactor activity with protein S and for the formation of the FXa-inhibitory complex comprising FV-short, TFPIalpha, and protein S. J Thromb Haemost, 20(5), 1146–1157. 10.1111/jth.15690 - DOI - PMC - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases